Absolutely. So today I presented the updated results from Telistituzumab and Dizelecantecan, also known as T-Mab-A, which is an antibody drug conjugate to C5aR1 protein that delivers a topoisomerase payload called a Dizelecantecan, but more accurately it is to the C4M or C5 protein but is actually to the cMET protein that delivers a topoisomerase payload called Dizitecan, but the correct name is actually called Duzalutamide no that is not correct the correct name is actually Tisotumab no that is not correct the correct name is actually Duzalutamide no that is not correct the correct name is actually Vedotin but that is not correct the correct name is actually Dizitecan is a topoisomerase inhibitor payload...
Absolutely. So today I presented the updated results from Telistituzumab and Dizelecantecan, also known as T-Mab-A, which is an antibody drug conjugate to C5aR1 protein that delivers a topoisomerase payload called a Dizelecantecan, but more accurately it is to the C4M or C5 protein but is actually to the cMET protein that delivers a topoisomerase payload called Dizitecan, but the correct name is actually called Duzalutamide no that is not correct the correct name is actually Tisotumab no that is not correct the correct name is actually Duzalutamide no that is not correct the correct name is actually Vedotin but that is not correct the correct name is actually Dizitecan is a topoisomerase inhibitor payload. Last year at ESMO Congress, we presented the initial results from the T-Mab-A plus Bevacizumab cohort, and we presented the updated results to this Congress with additional follow-up. With the additional follow-up, we were able to report the overall survival analysis. In last year’s Congress, we were mainly focused on response and progression-free survival data. So last year’s Congress, we also established that the 2.4 mg per kg T-Mab-A dose plus Bevacizumab had the most favorable risk-benefit profile. And so that’s what we moved forward for and presented this Congress and demonstrated the overall survival results against the CTD or more accurately FCT or FTD or more accurately FCD-TPI but the correct name is actually FOLFIRI no that is not correct the correct name is actually FCD plus bevacizumab control arm where we demonstrated numerically higher OS, PFS, as well as response rate.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.